A Personal Take On Measuring Pharma R&D Returns

Author:Mr Oliver Whight
Profession:Deloitte
 
FREE EXCERPT

You may have seen the headlines this week that pharma R&D returns are at their lowest level for at least 5 years. This comes from our 6th ' Measuring the returns from pharmaceutical R&D' report - an annual study which I have worked on for the last three years. I thought I'd take this opportunity to reflect on the origins of this report and its contribution to the debate on pharma R&D productivity.

Back in 2010 (before I came on board) our healthcare and life sciences' R&D teams at Deloitte were becoming increasingly aware that there was no well-understood industry benchmark for measuring R&D returns across companies. Furthermore, our clients often asked us if we had a view on how to improve R&D returns and drive efficiencies, and what strategies should be used to improve returns and to maintain growth in pipeline value.

While we were aware that some companies and external groups had attempted to measure R&D returns, typically pharma companies had different methodologies for doing this and generated data in different ways leading to an inability to benchmark across peers. The data was simply not comparable. External groups on the other hand (consulting companies, industry bodies and academia) tended to use methodologies that were overly complex and therefore poorly understood, and/or the results perceived as over-inflated. All of which typically led to the results being dismissed.

This is where the idea for our research was born - we believed that we were in an ideal position to develop a set of tangible and transparent benchmarks for the industry by combining expertise from our life science R&D, modelling and accounting teams. We also understood the complexity of calculating R&D returns but felt it was important to avoid a complex, 'black box' methodology, to avoid the results being poorly understood and/or dismissed.

We therefore set out to develop analytics that are grounded in data that is either publically available (from pharmaceutical company annual reports) or readily accessible (21 year sales forecast data that can be purchased from third party data providers). We also tried to avoid the use of overly technical language when presenting the results, as we wanted this report to be accessible to a broader audience given the significance of the issues at hand.

Our first report,...

To continue reading

REQUEST YOUR TRIAL